S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Stock ideas from the 2024 Microcap Conference
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
How major US stock indexes fared Friday, 2/23/2024
Better Than Oil Stocks (Ad)
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
MarketBeat Week in Review – 2/19 - 2/23
Obama’s 2024 Confession (Ad)
Closing prices for crude oil, gold and other commodities
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Stock ideas from the 2024 Microcap Conference
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
How major US stock indexes fared Friday, 2/23/2024
Better Than Oil Stocks (Ad)
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
MarketBeat Week in Review – 2/19 - 2/23
Obama’s 2024 Confession (Ad)
Closing prices for crude oil, gold and other commodities
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Stock ideas from the 2024 Microcap Conference
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
How major US stock indexes fared Friday, 2/23/2024
Better Than Oil Stocks (Ad)
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
MarketBeat Week in Review – 2/19 - 2/23
Obama’s 2024 Confession (Ad)
Closing prices for crude oil, gold and other commodities
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Stock ideas from the 2024 Microcap Conference
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
How major US stock indexes fared Friday, 2/23/2024
Better Than Oil Stocks (Ad)
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
MarketBeat Week in Review – 2/19 - 2/23
Obama’s 2024 Confession (Ad)
Closing prices for crude oil, gold and other commodities
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies
NASDAQ:XENE

Xenon Pharmaceuticals (XENE) Stock Price, News & Analysis

$49.46
+0.21 (+0.43%)
(As of 02/23/2024 ET)
Today's Range
$48.74
$49.51
50-Day Range
$41.00
$50.04
52-Week Range
$27.99
$50.98
Volume
296,356 shs
Average Volume
361,207 shs
Market Capitalization
$3.24 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$56.89

Xenon Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
15.0% Upside
$56.89 Price Target
Short Interest
Bearish
4.29% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.03mentions of Xenon Pharmaceuticals in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$447,120 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.83) to ($3.24) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.28 out of 5 stars

Medical Sector

548th out of 939 stocks

Pharmaceutical Preparations Industry

256th out of 439 stocks


XENE stock logo

About Xenon Pharmaceuticals Stock (NASDAQ:XENE)

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.

XENE Stock Price History

XENE Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Xenon’s Stock Rated Buy on Promising MDD and Epilepsy Drug Potential
See More Headlines
Receive XENE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xenon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
2/24/2024
Next Earnings (Confirmed)
2/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:XENE
Employees
203
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$56.89
High Stock Price Target
$63.00
Low Stock Price Target
$46.00
Potential Upside/Downside
+15.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Net Income
$-125,370,000.00
Pretax Margin
-123,568.95%

Debt

Sales & Book Value

Annual Sales
$9.43 million
Book Value
$11.54 per share

Miscellaneous

Free Float
61,877,000
Market Cap
$3.24 billion
Optionable
Optionable
Beta
1.19
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Ian C. Mortimer C.M.A. (Age 48)
    CPA, M.B.A., President, CEO & Director
    Comp: $973.76k
  • Ms. Sherry Aulin (Age 41)
    Chief Financial Officer
    Comp: $3.03M
  • Ms. Andrea DiFabio J.D. (Age 56)
    Chief Legal Officer & Corporate Secretary
    Comp: $200.51k
  • Dr. Christopher E. Von Seggern M.B.A. (Age 45)
    M.P.H., M.P.H. M.B.A, Ph.D., Chief Commercial Officer
    Comp: $618.07k
  • Dr. Christopher John Kenney M.D.Dr. Christopher John Kenney M.D. (Age 53)
    Chief Medical Officer
    Comp: $684.22k
  • Ms. Shelley McCloskey B.A. (Age 64)
    Executive Vice President of Human Resources
  • Dr. Robin P. Sherrington Ph.D. (Age 63)
    Executive Vice President of Strategy & Innovation
    Comp: $351.67k
  • Dr. James R. Empfield Ph.D. (Age 63)
    Executive Vice President of Drug Discovery
    Comp: $323.43k
  • Ms. Sheila M. Grant M.B.A.
    M.Sc., MBA, Executive Vice President of R&D Operations














XENE Stock Analysis - Frequently Asked Questions

Should I buy or sell Xenon Pharmaceuticals stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" XENE shares.
View XENE analyst ratings
or view top-rated stocks.

What is Xenon Pharmaceuticals' stock price target for 2024?

9 equities research analysts have issued 1 year price objectives for Xenon Pharmaceuticals' shares. Their XENE share price targets range from $46.00 to $63.00. On average, they predict the company's share price to reach $56.89 in the next twelve months. This suggests a possible upside of 15.0% from the stock's current price.
View analysts price targets for XENE
or view top-rated stocks among Wall Street analysts.

How have XENE shares performed in 2024?

Xenon Pharmaceuticals' stock was trading at $46.06 at the beginning of 2024. Since then, XENE stock has increased by 7.4% and is now trading at $49.46.
View the best growth stocks for 2024 here
.

Are investors shorting Xenon Pharmaceuticals?

Xenon Pharmaceuticals saw a increase in short interest in January. As of January 31st, there was short interest totaling 2,810,000 shares, an increase of 12.0% from the January 15th total of 2,510,000 shares. Based on an average trading volume of 662,600 shares, the short-interest ratio is presently 4.2 days.
View Xenon Pharmaceuticals' Short Interest
.

When is Xenon Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 29th 2024.
View our XENE earnings forecast
.

How can I listen to Xenon Pharmaceuticals' earnings call?

Xenon Pharmaceuticals will be holding an earnings conference call on Thursday, February 29th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Xenon Pharmaceuticals' earnings last quarter?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) released its quarterly earnings data on Wednesday, November, 8th. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, beating analysts' consensus estimates of ($0.75) by $0.02. During the same period in the prior year, the firm posted ($0.57) earnings per share.

What ETFs hold Xenon Pharmaceuticals' stock?
What other stocks do shareholders of Xenon Pharmaceuticals own?
Who are Xenon Pharmaceuticals' major shareholders?

Xenon Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Avoro Capital Advisors LLC (8.66%), Capital World Investors (4.10%), Capital International Investors (3.75%), Commodore Capital LP (3.31%), Braidwell LP (2.52%) and First Light Asset Management LLC (2.51%). Insiders that own company stock include Christopher John Kenney, Dawn Svoronos, Frank A Holler, Gary Patou, Ian Mortimer, James R Empfield, Seggern Christopher Von, Sherrington Robin and Simon N Pimstone.
View institutional ownership trends
.

How do I buy shares of Xenon Pharmaceuticals?

Shares of XENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:XENE) was last updated on 2/24/2024 by MarketBeat.com Staff